The estimated bioavailability of Semaglutide following oral administration is approximately 1% (source)
[PMID: 30605289] PubMed record related to this compound for laboratory literature review
[PubMed Central ID: PMC8660013]
As treatment options continue to grow, the future of care is becoming more individualized and responsive to the needs of people affected by obesity
When Cigna covers Zepbound, typical PA requirements include: BMI 30 or 27 with a comorbidity (hypertension, type 2 diabetes, OSA, or cardiovascular disease), 3 months of documented lifestyle modification (diet and exercise program), and you cannot be taking another GLP-1 medication simultaneously
GLP-3RT is a research-grade triple agonist peptide that activates GLP-1, GIP, and glucagon receptors